Smart Start:利妥昔单抗、来那度胺和依鲁替尼治疗新诊断大B细胞淋巴瘤
这项研究者发起的单臂II期试验纳入60例新诊断非生发中心B细胞样弥漫性大B细胞淋巴瘤(DLBCL)患者,先接受利妥昔单抗、来那度胺和依鲁替尼(RLI)两个周期,之后加标准化疗共六周期;两周期RLI后总缓解率为86.2%,RLI联合化疗结束时完全缓解率为94.5%,中位随访31个月时2年无进展生存率和总生存率分别为91.3%和96.6%。
要点
- 两周期RLI后总缓解率为86.2%,RLI联合化疗结束时完全缓解率为94.5%。
- 中位随访31个月,2年无进展生存率91.3%、总生存率96.6%。
- RLI是首个在新诊断DLBCL中化疗前使用靶向联合方案的研究。
核心结论
- Smart Start是首个在新诊断DLBCL中化疗前使用靶向联合方案的研究,RLI产生高总缓解率,RLI联合化疗带来持久缓解,为开发生物学驱动的非细胞毒性一线治疗奠定潜在基础。
研究设计与样本
- 研究者发起的单臂II期试验,纳入60例新诊断非生发中心B细胞样DLBCL患者,接受利妥昔单抗、来那度胺和依鲁替尼(RLI)序贯联合化疗(ClinicalTrials.gov标识:NCT02636322)。
- 给药方案:每21天周期第1天静脉利妥昔单抗375 mg/m2一次,第1-10天来那度胺25 mg每日一次,依鲁替尼560 mg每日一次持续给药;两周期后加标准化疗共六周期。
- 主要终点为两周期单独RLI后总缓解率和RLI联合化疗完成后完全缓解率;在可评估样本中进行循环肿瘤DNA和DLBCL90检测。
主要发现
- 中位年龄63.5岁(范围29-83岁),28%年龄≥70岁;修订国际预后指数评分为高危者占42%,62%为MYC和BCL2蛋白双表达。
- 两周期RLI后总缓解率为86.2%,RLI联合化疗结束时完全缓解率为94.5%。
- 中位随访31个月,2年无进展生存率为91.3%,2年总生存率为96.6%。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Chemoimmunotherapy for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) is largely unchanged for decades. Both preclinical models and clinical data suggest the combination of lenalidomide and ibrutinib may have synergy in DLBCL, particularly in the non-germinal center B-cell-like subset. METHODS: We enrolled 60 patients with newly diagnosed non-germinal center B-cell-like DLBCL in this investigator-initiated, single-arm phase II trial of rituximab, lenalidomide, and ibrutinib (RLI) with the sequential addition of chemotherapy (ClinicalTrials.gov identifier: NCT02636322). Patients were treated with rituximab 375 mg/m2 intravenous once on day 1, lenalidomide 25 mg once per day on days 1-10, and ibrutinib 560 mg once daily continuously of each 21-day cycle (RLI). After two cycles, standard chemotherapy was added to RLI for six additional cycles. The primary end points were overall response rate (ORR) after two cycles of RLI alone and complete response rate after completion of RLI with chemotherapy. In evaluable samples, circulating tumor DNA and DLBCL90 assays were performed. RESULTS: The median age was 63.5 years (range, 29-83 years) with 28% age 70 years or older. The revised international prognostic index identified 42% as high risk, and 62% were double expressor of MYC and BCL2 protein. The ORR after two cycles of RLI was 86.2%, and the complete response rate at the end of RLI-chemotherapy was 94.5%. With a median follow-up of 31 months, the progression-free survival and overall survival were at 91.3% and 96.6% at 2 years, respectively. CONCLUSION: Smart Start is the first study, to our knowledge, to treat newly diagnosed DLBCL with a targeted therapy combination before chemotherapy. RLI produced a high ORR, and RLI with chemotherapy resulted in durable responses. This establishes the potential for developing biologically driven and noncytotoxic first-line therapies for DLBCL.
引用
- Westin J, Davis RE, Feng L, et al. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin Oncol. 2022. PMID: 35952327. doi:10.1200/JCO.22.00597
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。